新型冠状病毒灭活疫苗BIBP-CorV的真实世界研究进展

Progress in real⁃world research on inactivated COVID⁃19 vaccine BIBP⁃CorV

北京生物制品研究所有限责任公司研发生产的新型冠状病毒灭活疫苗(Vero细胞,BIBP-CorV疫苗)相继完成了Ⅰ/Ⅱ、Ⅲ期临床试验,广泛应用于多个国家和地区。本文对BIBP-CorV疫苗在各国开展的真实世界研究进展作一综述,回顾总结了目前已报道的BIBP-CorV疫苗的真实世界研究数据,包括一般人群、高风险人群和特殊人群接种疫苗的有效性(vaccine effectiveness,VE)、免疫原性和安全性,为BIBP-CorV疫苗在大样本量的广泛人群中使用提供参考。

PhaseⅠ/ⅡandⅢclinical trials of inactivated COVID-19 vaccine(Vero cells,BIBP-CorV vaccine),developed and manufactured by Beijing Institute of Biological Products Co.,Ltd.,has been completed,and the vaccine is widely used in various countries and regions.This paper reviews the progress in real-world research on BIBP-CorV vaccine in various countries or regions,and summarizes the reported data on real-world research of BIBP-CorV vaccine,including the effectiveness,immunogenicity and safety in the general,high-risk and special populations,which provides a reference for the wide application of BIBP-CorV vaccine in populations from whom a large quantity of samples are taken.